肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Adaptimmune和Noile-Immune宣布合作，开发增强型SPEAR T细胞肿瘤免疫疗法

2019-08-28 不详 MedSci原创

AdaptimmuneNoile-ImmuneIL-7CCL19SPEART细胞肿瘤免疫疗法
关注

治疗癌症的T细胞疗法的领导者Adaptimmune Therapeutics和日本东京的创新型癌症免疫疗法Noile-Immune Biotech公司宣布，将共同开发下一代共同表达IL-7和CCL19的SPEAR T细胞产品，并结合Noile-Immune的PRIME（增殖诱导和迁移增强）技术。

治疗癌症的T细胞疗法的领导者Adaptimmune Therapeutics和日本东京的创新型癌症免疫疗法Noile-Immune Biotech公司宣布，将共同开发下一代共同表达IL-7和CCL19的SPEAR T细胞产品，并结合Noile-Immune的PRIME（增殖诱导和迁移增强）技术。

"我们最近开始了我们的肉瘤2期临床试验，称为SPEARHEAD-1以及SURPASS试验，这是我们的第一个下一代产品临床试验。我们将继续开发增强型产品，旨在提高抗肿瘤的疗效和耐久性回应"，Adaptimmune管道研究高级副总裁Karen Miller说，"与Noile-Immune的合作使我们制备能够分泌IL-7和CCL19的下一代SPEAR T细胞，这不仅可以改善我们设计的SPEAR T细胞的增殖和运输，还可以改善患者自身的T-细胞。这种增强的T细胞增殖和运输可以增强癌症患者的抗肿瘤活性。"

Adaptimmune将拥有在全球范围内开发和商业化最终产品的专有权。Adaptimmune将在所有计划中向Noile-Immune支付高达3.12亿美元的现金支付和里程碑付款。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2020-07-25 一闲

    #Adaptimmune#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-11-25 智慧医人

    #Oil#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-10-04 kalseyzl

    #ADAP#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2020-07-10 feather89

    #PE#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2020-07-17 xlysu

    #SPEAR#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 般若傻瓜

    #ADA#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 mnda

    #DAPT#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 quxin068

    #immune#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1779038, encodeId=db2b1e79038df, content=<a href='/topic/show?id=c1a41946d9' target=_blank style='color:#2F92EE;'>#Adaptimmune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1946, encryptionId=c1a41946d9, topicName=Adaptimmune)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Jul 25 06:41:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921041, encodeId=246c19210419c, content=<a href='/topic/show?id=f9af13291a4' target=_blank style='color:#2F92EE;'>#Oil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13291, encryptionId=f9af13291a4, topicName=Oil)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Nov 25 20:41:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779027, encodeId=896f1e790270e, content=<a href='/topic/show?id=5e05194410' target=_blank style='color:#2F92EE;'>#ADAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1944, encryptionId=5e05194410, topicName=ADAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Fri Oct 04 11:41:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728118, encodeId=e96b1e2811834, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jul 10 08:41:00 CST 2020, time=2020-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794256, encodeId=35421e9425646, content=<a href='/topic/show?id=78181659647' target=_blank style='color:#2F92EE;'>#SPEAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16596, encryptionId=78181659647, topicName=SPEAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f54230, createdName=xlysu, createdTime=Fri Jul 17 18:41:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264725, encodeId=056c1264e25fe, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374352, encodeId=7f1513e435243, content=<a href='/topic/show?id=6d5d56912e' target=_blank style='color:#2F92EE;'>#DAPT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5691, encryptionId=6d5d56912e, topicName=DAPT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519411, encodeId=b50f1519411c9, content=<a href='/topic/show?id=e0e49e6858' target=_blank style='color:#2F92EE;'>#immune#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9768, encryptionId=e0e49e6858, topicName=immune)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521491, encodeId=b163152149198, content=<a href='/topic/show?id=0e108281e8f' target=_blank style='color:#2F92EE;'>#肿瘤免疫疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82817, encryptionId=0e108281e8f, topicName=肿瘤免疫疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=995711357332, createdName=drwjr, createdTime=Fri Aug 30 04:41:00 CST 2019, time=2019-08-30, status=1, ipAttribution=)]
    2019-08-30 drwjr

    #肿瘤免疫疗法#

    0